PeptideAgentAsk PeptideAgent
News / Source-backed

What changed—and what the evidence says.

Source-backed peptide news, timely analysis, and evergreen evidence guides. Event dates, review dates, research types, and decision boundaries stay separate.
Editorial standard

LATEST ANALYSIS

Record update log
Regulation

FDA revises its playbook for generic peptide products

Seventeen revised draft product-specific guidances explain the evidence FDA expects for certain generic peptide applications.

Read the source-backed analysis

NEWS ARCHIVE

Every update keeps its boundary.

Reporting is added only when a primary or official source can be linked directly.

Clinical trials

Retatrutide clears two more Phase 3 readouts—but remains investigational

Lilly reported positive topline TRIUMPH-2 and TRIUMPH-3 results. The data are important, but they are not an FDA approval.

Reviewed August 8, 2026
Regulation

FDA clarifies compounded GLP-1 policy after supply stabilizes

The agency restated the legal boundary between limited compounding exceptions and routine copies of approved GLP-1 medicines.

Reviewed August 8, 2026
Sport status

The 2026 WADA Prohibited List is now in force

The annual list took effect January 1. Sport status still has to be checked separately from approval and clinical evidence.

Reviewed August 8, 2026

PEPTIDE GUIDES

Research every peptide by intent.

Browse all 24 guides
Recovery3 sources

BPC-157

Interest in BPC-157 is driven by broad preclinical findings. The central evidence gap is not whether animal signals exist, but whether a defined product is safe and effective in people.

Evidence · research · status · limits
Weight & Metabolism3 sources

Retatrutide

Retatrutide has meaningful randomized human evidence, but it should not be described as an available approved alternative to semaglutide or tirzepatide.

Evidence · research · status · limits
Growth Hormone3 sources

Tesamorelin

Tesamorelin has the strongest human evidence in a narrow, labeled population. Evidence from that population should not be generalized to routine weight management.

Evidence · research · status · limits
Longevity3 sources

MOTS-c

MOTS-c is biologically interesting, but human physiology observations are frequently mistaken for evidence that an exogenous product improves health or performance.

Evidence · research · status · limits
Recovery2 sources

TB-500

The first question for TB-500 is entity identity: evidence about full-length thymosin beta-4 should not be treated as direct evidence for every TB-500 product.

Evidence · research · status · limits
Growth Hormone2 sources

Ipamorelin

Ipamorelin has human exposure data, but the evidence base is narrow and does not validate generalized anti-aging or body-composition claims.

Evidence · research · status · limits